Premium
Levomepromazine receptor binding profile in human brain—implications for treatment—resistant schizophrenia
Author(s) -
Nair N. P. V.,
Cecyre D.,
Quirion R.,
Lal S.
Publication year - 1993
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1993.tb03391.x
Subject(s) - levomepromazine , clozapine , schizophrenia (object oriented programming) , chlorpromazine , pharmacology , psychotomimetic , psychosis , receptor , phencyclidine , medicine , psychology , psychiatry , nmda receptor , dopamine , haloperidol
The receptor binding profile of levomepromazine (LMP) in human brain was compared with that of clozapine (CLOZ) and chlorpromazine (CPZ). LMP showed significantly greater binding affinity for both α‐1 and serotonin‐2 binding sites than either CLOZ or CPZ, and significantly greater binding to α‐2 sites than CPZ. A potent pharmacological effect at these receptor sites may explain the beneficial effect of LMP on psychotic symptoms and akathisia in treatment‐resistant schizophrenia recently described in 2 open studies. LMP requires further appraisal as a potentially useful neuroleptic in the management of treatment‐resistant schizophrenia.